Compare Omnicom Group Inc. (OMC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Omnicom Group Inc. trades at $79.2 (market cap $22.58B), while Vertex Pharmaceuticals Incorporated trades at $472.52 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.4× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays a 4.04% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| OMC | VRTX | |
|---|---|---|
Market Cap | $22.58B | $122.33B |
Sector | Media | Health |
52-Week High | $85.80 | $529.59 |
52-Week Low | $67.27 | $366.54 |
Enterprise Value | $29.80B | $117.07B |
Dividend Yield | 4.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $79.21, down 3.08% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings, beating expectations with $1.90 EPS versus $1.82 expected, but Q4 2025 missed at $2.59 versus $2.72. Revenue growth is strong, reaching $17.27 billion in 2025, though net income was negative $54.50 million due to elevated taxes. Analyst consensus is mixed with 32% buy ratings and a $105.75 price target, representing significant upside. Recent news highlights major client wins including IBM's global media account and partnerships with Netflix and Disney.
OMC presents a value opportunity with a low P/E of 12.16 and P/S of 0.96, trading below analyst targets. The advertising holding company benefits from AI platform expansion and strategic partnerships, but faces margin pressure and intense competition. Near-term catalysts include Q2 2026 earnings on July 28, 2026, where the company must deliver on the expected $2.58 EPS to maintain investor confidence amid current bearish sentiment.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
